June 2026 |Building the Opioid-Sparing Protocol: What the Preclinical Data Actually Says

VITALS Newsletter — by Niki DeValk, AAS, LVT, SRS

Interventional & Surgical Specialist | Owner, NiKara Preclinical

Let’s Dive In

Hi everyone —

Across both clinical medicine and translational research, the conversation around pain management has shifted dramatically over the past decade. Opioids remain an important part of perioperative analgesia, but multimodal strategies are increasingly recognized as the more stable, more humane, and more translationally relevant approach.

In preclinical research, this shift is complicated by species differences in pain expression, drug metabolism, pharmacokinetics, and validated assessment tools. Many opioid‑sparing protocols blend species‑specific evidence with veterinary clinical experience and extrapolation from human medicine — which raises an important question:

What do we actually know, and where are we still making educated assumptions?

Why This Topic Matters

Multimodal analgesia aims to target multiple points in the pain cascade simultaneously. Instead of relying on a single drug class, protocols combine opioids, NSAIDs, local anesthetics, NMDA antagonists, alpha‑2 agonists, gabapentinoids, and regional anesthesia techniques.

The goal is straightforward:

• Reduce overall pain burden

• Improve recovery quality

• Minimize opioid‑related adverse effects

• Maintain physiologic stability

• Enhance translational relevance

In large animal models, these benefits often extend beyond welfare — reducing inhalant anesthetic requirements and improving procedural consistency.

Key Insights

• Multimodal analgesia is not about eliminating opioids — it’s about reducing reliance on them.

• Species differences significantly influence protocol design and effectiveness.

• NSAIDs and local anesthetics consistently improve comfort across multiple models.

• Regional anesthesia is becoming one of the most impactful opioid‑sparing tools.

• Many protocols still rely on extrapolation due to limited species‑specific data.

What’s Changing

The opioid‑sparing movement is accelerating across preclinical research. Regional anesthesia techniques, continuous local anesthetic infusions, ketamine CRIs, dexmedetomidine adjuncts, and long‑duration local anesthetics are increasingly incorporated into perioperative plans.

As ultrasound guidance becomes more accessible, regional blocks are transitioning from “advanced options” to standard components of many surgical models.

Clinical Connections

Human medicine has long embraced multimodal analgesia to reduce opioid exposure, improve recovery, and stabilize physiology. Veterinary medicine mirrors this approach, especially in canine and swine models where evidence is strongest.

Translationally, multimodal protocols improve:

• physiologic stability

• recovery quality

• consistency across subjects

• alignment with clinical standards

However, many species — particularly goats and certain ovine models — still lack robust pharmacokinetic and pain‑scoring validation.

Case Study: How This Shows Up in Real Work

The scenario: A large‑animal orthopedic study was relying heavily on opioid‑only analgesia. While animals appeared outwardly stable, recovery behavior was inconsistent, inhalant requirements were elevated, and pain scoring was difficult due to subtle species‑specific behaviors.

The pivot: The team incorporated meloxicam, a TAP block, and a ketamine CRI into the perioperative plan. Opioids were retained but used more sparingly.

The outcome: Recovery became smoother and more predictable. Inhalant requirements dropped, physiologic parameters stabilized, and pain scoring became more reliable. The multimodal plan reduced variability and improved both welfare and data quality.

The takeaway: Multimodal analgesia doesn’t just improve comfort — it improves the consistency and interpretability of your study outcomes.

Practical Takeaways

• Start with validated species‑specific evidence whenever possible.

• Incorporate local and regional anesthesia early — these techniques often provide the greatest opioid‑sparing benefit.

• Match analgesia to procedure severity — minimally invasive survival procedures and thoracotomies should not receive identical plans.

• Monitor outcomes objectively:

  • recovery quality

  • food intake

  • behavior

  • physiologic parameters

  • rescue analgesia requirements

• Recognize where evidence is strong — and where it’s still thin.

Wrapping Up

The movement toward opioid‑sparing analgesia isn’t about removing opioids from the toolbox. It’s about building evidence‑based, multimodal frameworks that improve welfare, stabilize physiology, and strengthen translational relevance.

For swine, canine, and many ovine models, the evidence is increasingly robust. For caprine and specialty species, significant gaps remain — and thoughtful protocol development is essential.

At NiKara Preclinical, my approach is simple: use the best available evidence, acknowledge where evidence is lacking, and refine protocols based on objective outcomes.

Stay sharp. Stay supported. Stay vital.

— Niki

Niki DeValk, AAS, LVT, SRS‍ ‍

Interventional & Surgical Specialist | Owner, NiKara Preclinical

📧 niki@nikarapreclinical.com 🌐 www.nikarapreclinical.com